Rifaximin plus fibre versus fibre alone in preventing diverticulitis recurrence: A (problematic) trial to tackle an epidemiologically relevant problem

Digestive and Liver Disease

Volumn 45, Issue 2, 2013, Pages 102-103

  Conte, Dario ^a   Orlando, Stefania ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAXIMIN;

ANTIBIOTIC THERAPY; COLON DIVERTICULOSIS; FIBER; FOLLOW UP; HEALTH CARE COST; HUMAN; INTERNAL VALIDITY; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SAMPLE SIZE;

DIETARY FIBER; DIVERTICULITIS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; RIFAMYCINS;

EID: 84872394608     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.12.003     Document Type: Note

References (5)

1. Lanas A., Ponce J., Bignamini A., Mearin F. Rifaximin plus fiber supplementation versus fiber supplementation alone to prevent diverticulitis recurrence: a proof-of-concept study. Digestive and Liver Disease 2013, 45:103-108.
2. Farmakis N., Tudor R.G., Keighley M.R. The 5-year natural history of complicated diverticular disease. British Journal of Surgery 1994, 81:733-735.
3. Kang J.Y., Melville D., Maxwell J.D. Epidemiology and management of diverticular disease of the colon. Drugs and Aging 2004, 2:211-228.
4. Comparato G., Di Mario F. Recurrent diverticulitis. Journal of Clinical Gastroenterology 2008, 42:1130-1134.
5. Hall J.F., Roberts P.L., Ricciardi R., et al. Long-term follow-up after an initial episode of diverticulitis: what are the predictors of recurrence. Diseases of the Colon and Rectum 2011, 54:283-288.